Takeda Pharmaceutical Co company info

What does Takeda Pharmaceutical Co do?
Takeda Pharmaceutical (TSE:4502), (NYSE:TAK) is a global biopharmaceutical company focused on bringing forward innovative medicines and treatments to patients worldwide. Its operations span across several therapeutic areas, including oncology, gastroenterology, neuroscience, and rare diseases. Takeda is continually working on research and development projects, aiming to deliver life-transforming treatments and tackle unmet medical needs. The company's objective is not only to drive scientific discovery but also to ensure access to its medicines for people who need them the most, demonstrating a commitment to better health and a brighter future for millions around the globe.
Takeda Pharmaceutical Co  company media
Company Snapshot

Is Takeda Pharmaceutical Co a public or private company?

key
Ownership
Public

How many people does Takeda Pharmaceutical Co employ?

people
Employees
36,680

What sector is Takeda Pharmaceutical Co in?

pie chart
Sector
Health Care

Where is the head office for Takeda Pharmaceutical Co ?

location pin
Head Office
Tokyo, Japan

What year was Takeda Pharmaceutical Co founded?

founded flag
Year Founded
1781
What does Takeda Pharmaceutical Co specialise in?
/Drug Development /Market Expansion /Healthcare Technology /Drug Sales /Patient Services /Research Projects

What are the products and/or services of Takeda Pharmaceutical Co ?

Overview of Takeda Pharmaceutical Co offerings
Entyvio, a monoclonal antibody for the treatment of certain chronic inflammatory bowel diseases.
Vyvanse, is an is FDA-approved to treat attention deficit hyperactivity disorder (ADHD) in adults and in children who are at least 6 years old.
Velcade, a proteasome inhibitor for the treatment of multiple myeloma and mantle cell lymphoma.
Dexilant, a proton pump inhibitor for healing and maintenance of erosive esophagitis.
Alunbrig, a tyrosine kinase inhibitor for treating ALK-positive metastatic non-small cell lung cancer.
Adynovate, a modified human coagulation factor VIII for use in Hemophilia A patients.

Who is in the executive team of Takeda Pharmaceutical Co ?

Takeda Pharmaceutical Co leadership team
  • Mr. Christophe  Weber
    Mr. Christophe Weber
    President, CEO & Representative Director
  • Dr. Andrew S.  Plump
    Dr. Andrew S. Plump
    President of Research & Development and Representative Director
  • Dr. Seigo  Izumo
    Dr. Seigo Izumo
    Chair of Management Board
  • Mr. Milano  Furuta
    Mr. Milano Furuta
    Chief Financial Officer
  • Mr. Haruhiko  Hirate
    Mr. Haruhiko Hirate
    Member of Management Board
  • Mr. Salvatore  Alesci M.D., Ph.D.
    Mr. Salvatore Alesci M.D., Ph.D.
    Member of Management Board and Head of R&D Global Science & Biomedical Policy
  • Norimasa  Takeda
    Norimasa Takeda
    Chief Accounting Officer & Corporate Controller
  • Mr. Iwaaki  Taniguchi
    Mr. Iwaaki Taniguchi
    Senior Vice President of Corporate Finance & Controlling Department